Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31557880 | 0.89 | CYP17A1 (0.51) | CA12CA1CA9ATRCYP17A1 | |
| SCHEMBL4984917 | 0.88 | CA12 (0.52) | CA12CA1CA9ATRSMN1; SMN2 | |
| SCHEMBL31557915 | 0.88 | CYP17A1 (0.44) | CA12CA1CA9ATRSMN1; SMN2 | |
| SCHEMBL509152 | 0.87 | CA12 (0.53) | CA12CA1CA9ALDH1A1GAA | |
| SCHEMBL9081119 | 0.85 | SMN1; SMN2 (0.66) | CA12CA1CA9ATRSMN1; SMN2 | |
| SCHEMBL24730061 | 0.84 | ATR (0.47) | CA12CA1CA9ATRSMN1; SMN2 | |
| SCHEMBL21352074 | 0.84 | ATR (0.47) | CA12CA1CA9ATRSMN1; SMN2 | |
| SCHEMBL30641926 | 0.84 | ATR (0.47) | CA12CA1CA9ATRSMN1; SMN2 | |
| SCHEMBL4415627 | 0.84 | ALDH1A1 (0.53) | CA12CA1CA9ATRSMN1; SMN2 | |
| SCHEMBL17822878 | 0.84 | ATR (0.47) | CA12CA1CA9ATRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108383789-A | Pyrazole compound as CRTH2 antagonists | 艾克提麦斯医药品有限公司 | 2018-08-10 | — | — | CN | disclosed |
| EP-2528901-B9 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-25 | — | — | EP | disclosed |
| CN-102884051-B | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-16 | — | — | CN | disclosed |
| CN-104829535-A | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INT | 2015-08-12 | — | — | CN | disclosed |
| EP-2528901-B1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-8791272-B2 | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2094272-B1 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2528901-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092140-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7834023-B2 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834023-B2 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH3 | CA12 4515/4885CA1 4167/4885CA9 3938/4885 |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | TBXA2R, F2R, PTGER1 | CA12 4849/4885CA1 4479/4885CA9 4726/4885 |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, PTAFR, PLAT | CA12 4555/4885CA1 4597/4885CA9 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.